Quick Answer
MiNK Therapeutics, Inc. reported R&D Expense of $5.76 million for fiscal year 2025.
MiNK Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.76M | -9.1% |
| 2024 | $6.34M | -59.1% |
| 2023 | $15.49M | -33.0% |
| 2022 | $23.12M | +65.5% |
| 2021 | $13.97M | +46.9% |
| 2020 | $9.51M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.14M | +111.4% | -37.8% |
| June 30, 2025 | $1.84M | -0.0% | +45.7% |
| March 31, 2025 | $1.26M | -50.5% | +133.4% |
| September 30, 2024 | $540.6K | -84.2% | -70.6% |
| June 30, 2024 | $1.84M | -59.6% | -27.8% |
| March 31, 2024 | $2.55M | -39.2% | -25.6% |
| September 30, 2023 | $3.43M | -44.3% | -24.8% |
| June 30, 2023 | $4.56M | -22.4% | +8.7% |
- MiNK Therapeutics, Inc. showed a decrease of -9.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, MiNK Therapeutics, Inc.’s r&d expense has declined by 39.5% (from $9.51 million to $5.76 million).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: